Literature DB >> 19369208

Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice.

Min Wu1, Lina Jung, Adrian B Cooper, Christina Fleet, Lihao Chen, Lyne Breault, Kimberly Clark, Zuhua Cai, Sylvie Vincent, Steve Bottega, Qiong Shen, Andrea Richardson, Marcus Bosenburg, Stephen P Naber, Ronald A DePinho, Charlotte Kuperwasser, Murray O Robinson.   

Abstract

Breast cancer development is a complex pathobiological process involving sequential genetic alterations in normal epithelial cells that results in uncontrolled growth in a permissive microenvironment. Accordingly, physiologically relevant models of human breast cancer that recapitulate these events are needed to study cancer biology and evaluate therapeutic agents. Here, we report the generation and utilization of the human breast cancer in mouse (HIM) model, which is composed of genetically engineered primary human breast epithelial organoids and activated human breast stromal cells. By using this approach, we have defined key genetic events required to drive the development of human preneoplastic lesions as well as invasive adenocarcinomas that are histologically similar to those in patients. Tumor development in the HIM model proceeds through defined histological stages of hyperplasia, DCIS to invasive carcinoma. Moreover, HIM tumors display characteristic responses to targeted therapies, such as HER2 inhibitors, further validating the utility of these models in preclinical compound testing. The HIM model is an experimentally tractable human in vivo system that holds great potential for advancing our basic understanding of cancer biology and for the discovery and testing of targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19369208      PMCID: PMC2669443          DOI: 10.1073/pnas.0811785106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

Review 1.  HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer.

Authors:  S Ménard; P Casalini; M Campiglio; S Pupa; R Agresti; E Tagliabue
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

Review 2.  Monoclonal antibody therapy for breast cancer: herceptin.

Authors:  Richard S Finn; Dennis J Slamon
Journal:  Cancer Chemother Biol Response Modif       Date:  2003

3.  Reconstruction of functionally normal and malignant human breast tissues in mice.

Authors:  Charlotte Kuperwasser; Tony Chavarria; Min Wu; Greg Magrane; Joe W Gray; Loucinda Carey; Andrea Richardson; Robert A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-29       Impact factor: 11.205

4.  Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients.

Authors:  Yoshihisa Umekita; Yasuyo Ohi; Yoshiatsu Sagara; Hiroki Yoshida
Journal:  Int J Cancer       Date:  2002-03-20       Impact factor: 7.396

5.  Multiple developmental pathways of highly aggressive breast cancers disclosed by comparison of histological grades and c-erbB-2 expression patterns in both the non-invasive and invasive portions.

Authors:  H Tsuda; S Hirohashi
Journal:  Pathol Int       Date:  1998-07       Impact factor: 2.534

6.  Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase.

Authors:  Jean J Zhao; Ole V Gjoerup; Romesh R Subramanian; Yuan Cheng; Wen Chen; Thomas M Roberts; William C Hahn
Journal:  Cancer Cell       Date:  2003-05       Impact factor: 31.743

7.  A novel method for growing human breast epithelium in vivo using mouse and human mammary fibroblasts.

Authors:  Hema Parmar; Peter Young; Joanne T Emerman; Richard M Neve; Shanaz Dairkee; Gerald R Cunha
Journal:  Endocrinology       Date:  2002-12       Impact factor: 4.736

8.  p53 mutations in breast cancer.

Authors:  C Coles; A Condie; U Chetty; C M Steel; H J Evans; J Prosser
Journal:  Cancer Res       Date:  1992-10-01       Impact factor: 12.701

9.  HER-2/neu oncogene expression, DNA ploidy and proliferation index in breast cancer.

Authors:  S S Bacus; D M Chin; R K Stern; R Ortiz; S G Ruby; D S Weinberg
Journal:  Anal Quant Cytol Histol       Date:  1992-12       Impact factor: 0.302

10.  Activated neu induces rapid tumor progression.

Authors:  C T Guy; R D Cardiff; W J Muller
Journal:  J Biol Chem       Date:  1996-03-29       Impact factor: 5.157

View more
  27 in total

Review 1.  Telomeres and telomerase in cancer.

Authors:  Steven E Artandi; Ronald A DePinho
Journal:  Carcinogenesis       Date:  2009-11-03       Impact factor: 4.944

Review 2.  Non-germline genetically engineered mouse models for translational cancer research.

Authors:  Joerg Heyer; Lawrence N Kwong; Scott W Lowe; Lynda Chin
Journal:  Nat Rev Cancer       Date:  2010-07       Impact factor: 60.716

Review 3.  Pleiotropic functions of Rho GTPase signaling: a Trojan horse or Achilles' heel for breast cancer treatment?

Authors:  P R McHenry; T Vargo-Gogola
Journal:  Curr Drug Targets       Date:  2010-09       Impact factor: 3.465

4.  Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas.

Authors:  Yinghui Zhou; William M Rideout; Tong Zi; Angela Bressel; Shailaja Reddypalli; Rebecca Rancourt; Jin-Kyeung Woo; James W Horner; Lynda Chin; M Isabel Chiu; Marcus Bosenberg; Tyler Jacks; Steven C Clark; Ronald A Depinho; Murray O Robinson; Joerg Heyer
Journal:  Nat Biotechnol       Date:  2009-12-20       Impact factor: 54.908

5.  Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate.

Authors:  Theresa A Proia; Patricia J Keller; Piyush B Gupta; Ina Klebba; Ainsley D Jones; Maja Sedic; Hannah Gilmore; Nadine Tung; Stephen P Naber; Stuart Schnitt; Eric S Lander; Charlotte Kuperwasser
Journal:  Cell Stem Cell       Date:  2011-02-04       Impact factor: 24.633

Review 6.  Studying therapy response and resistance in mouse models for BRCA1-deficient breast cancer.

Authors:  Ewa Malgorzata Michalak; Jos Jonkers
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-02-18       Impact factor: 2.673

7.  Mechanisms of epigenetic silencing of the Rassf1a gene during estrogen-induced breast carcinogenesis in ACI rats.

Authors:  Athena Starlard-Davenport; Volodymyr P Tryndyak; Smitha R James; Adam R Karpf; John R Latendresse; Frederick A Beland; Igor P Pogribny
Journal:  Carcinogenesis       Date:  2009-12-14       Impact factor: 4.944

8.  Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer.

Authors:  H Wong; S Lau; T Yau; P Cheung; R J Epstein
Journal:  Br J Cancer       Date:  2010-04-27       Impact factor: 7.640

Review 9.  Stroma in breast development and disease.

Authors:  Lisa M Arendt; Jenny A Rudnick; Patricia J Keller; Charlotte Kuperwasser
Journal:  Semin Cell Dev Biol       Date:  2009-10-24       Impact factor: 7.727

Review 10.  c-Jun N-Terminal Kinases Mediate a Wide Range of Targets in the Metastatic Cascade.

Authors:  Nancy D Ebelt; Michael A Cantrell; Carla L Van Den Berg
Journal:  Genes Cancer       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.